The basis for entering the ‘imiglucerase’ market worth about 25 billion won
[팜뉴스=이권구 기자] Isu Abgis announced on the 5th that it had obtained 200,400 units of ‘Absertine’, a Gaucher disease treatment drug, from the Algerian Ministry of Food and Drug Safety on October 3rd.
The approved indication is “Long-term enzyme replacement in patients diagnosed with Type I Gaucher disease who present with one or more of the following symptoms: anemia due to causes other than iron deficiency, thrombocytopenia, bone disease due to causes other than vitamin D deficiency, hepatomegaly, or splenomegaly. use of therapy’. Isu Abgis applied for product approval on November 6, 2017, and received approval in about 4 years.
The company explained that this approval has laid the foundation for entering the imiglucerase market worth about 25 billion won and provided an opportunity to increase sales.
Isu Abgis plans to secure 50% of the market share through gradual market expansion.
Copyright © Farm News Unauthorized reproduction and redistribution prohibited
